Core Viewpoint - The approval of JMT206, a monoclonal antibody drug developed by the company, marks a significant advancement in clinical trials for obesity management in China [1] Group 1: Product Development - The drug JMT206 has received approval from the National Medical Products Administration to conduct clinical trials in China [1] - JMT206 specifically binds to activin receptors IIA and IIB, blocking the interaction of activin A, myostatin, and growth differentiation factor 11 with the type II activin receptor [1] - The mechanism of action aims to inhibit downstream signaling pathways, reducing muscle loss and promoting skeletal muscle maintenance and growth, thereby achieving muscle gain and fat loss [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight and have at least one weight-related comorbidity [1] - The product may also assist GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1]

该产品可同时特异性结合激活素受体IIA型(ActRIIA)与IIB型(ActRIIB)，阻断激活素A(ActivinA)、肌抑 素(GDF8)以及生长分化因子11(GDF11)与激活素受体II型(ActRII)的结合，从而抑制下游信号通路的激 活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1 受体激动剂实现更高质量的减重疗效。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并 症人群的体重管理。 格隆汇11月26日丨石药集团(01093.HK)宣布，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体药物 (JMT206)(「该产品」)已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。 临床前研究显示，该产品表现出较高的生物利用度以及良好的疗效和安全性，具有较高的临床开发价 值。 ...